InvestorsHub Logo

madrose1

09/04/12 6:54 AM

#128748 RE: glassy #128690

$MDVN price target raised to $134 from $119 at William Blair

MDVN target raised to $122 from $113 at Jefferies
Jefferies raised its price target for Medivation after Xtandi won FDA approval three months earlier than expected. The firm found the drug's label in-line with expectations and reiterates a Buy rating on the stock.

fridays , never a good time to short momo biotechs when FDA usually does their releases